Cat. No.: HY-50101C

Mavorixafor hydrochloride

(Synonyms: AMD-070 hydrochloride; AMD-11070 hydrochloride)

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively. Mavorixafor hydrochloride can be used for the study of WHIM syndrome.

For research use only. We do not sell to patients.

Purity: 99.64%
CAS No.: 880549-30-4
Formula: C₂₁H₂₈ClN₅
Molecular Weight:385.93

Storage:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Mavorixafor hydrochloride Chemical Structure

CAS No.: 880549-30-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

¹²⁵I-CXCL12-CXCR4

13 nM (IC₅₀)

HIV-1 (NL4.3 strain)

1 nM (IC₅₀, In MT-4 cells)

HIV-1 (NL4.3 strain)

9 nM (IC₅₀, In PBMCs)

HIV-1 (NL4.3 strain)

3 nM (IC90, In MT-4 cells)

HIV-1 (NL4.3 strain)

26 nM (IC90, In PBMCs)

All CXCR Isoforms :

All HIV Isoforms :

In Vitro

Mavorixafor (AMD-070) hydrochloride shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)^[1].
Mavorixafor (6.6 μM; 14-21 days) hydrochloride significantly suppresses the anchorage-dependent growth of the B88-SDF-1 cells. Mavorixafor hydrochloride significantly impaires the enhanced motility of B88-SDF-1 cells. Mavorixafor hydrochloride also significantly inhibits the migration and Matrigel invasion of B88-SDF-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Invasion Assay^[2]

Cell Line:

B88-SDF-1 cells
Concentration:

6.6 µM
Incubation Time:

48 h
Result:

Significantly inhibited the migration and Matrigel invasion of B88-SDF-1 cells.

In Vivo

Mavorixafor (2 mg/kg; po; once a day; for 49 days) hydrochloride significantly inhibits the lung metastasis of B88 SDF 1 cells in nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (8 weeks of age) injected with B88-SDF-1 cells^[2]
Dosage:

2 mg/kg
Administration:

Oral administration; once a day; for 49 days
Result:

A significant reduction in the number of metastatic lung nodules was observed in the mice.

Chemical Information

CAS No. 880549-30-4
Appearance Viscous Liquid
Molecular Weight 385.93
Formula C₂₁H₂₈ClN₅
Color Light yellow to brown
SMILES

NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]3CCCC4=C3N=CC=C4.[H]Cl
Synonyms

AMD-070 hydrochloride; AMD-11070 hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (8)

All

Sort by:

Journal Impact Factor

Proc Natl Acad Sci U S A

Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists. [Abstract]

2025 Mar 18;122(11):e2425795122. PMID: 40063796
Cell Mol Life Sci

Crosstalk between purinergic receptor P2Y11 and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages. [Abstract]

2024 Mar 13;81(1):132. PMID: 38472446
Am J Physiol Cell Physiol

Mechanistic insights into SENP1 and OCT4 interaction in promoting drug resistance and stem cell features in colon cancer. [Abstract]

2025 Apr 1;328(4):C1260-C1278. PMID: 40063360
Oncol Rep

Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. [Abstract]

2022 Apr;47(4):68. PMID: 35119076
Biosci Rep

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs. [Abstract]

2023 Dec 22;43(12):BSR20230981. PMID: 38131305
Br J Haematol

CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance. [Abstract]

2023 May;201(3):459-469. PMID: 36535585
PLoS One

Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. [Abstract]

2016 Mar 21;11(3):e0151765. PMID: 26998906
Patent

US20220273751A1.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (259.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5911 mL

12.9557 mL

25.9114 mL

5 mM

0.5182 mL

2.5911 mL

5.1823 mL

10 mM

0.2591 mL

1.2956 mL

2.5911 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88. [Content Brief]

[2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5911 mL	12.9557 mL	25.9114 mL	64.7786 mL
	5 mM	0.5182 mL	2.5911 mL	5.1823 mL	12.9557 mL
	10 mM	0.2591 mL	1.2956 mL	2.5911 mL	6.4779 mL
	15 mM	0.1727 mL	0.8637 mL	1.7274 mL	4.3186 mL
	20 mM	0.1296 mL	0.6478 mL	1.2956 mL	3.2389 mL
	25 mM	0.1036 mL	0.5182 mL	1.0365 mL	2.5911 mL
	30 mM	0.0864 mL	0.4319 mL	0.8637 mL	2.1593 mL
	40 mM	0.0648 mL	0.3239 mL	0.6478 mL	1.6195 mL
	50 mM	0.0518 mL	0.2591 mL	0.5182 mL	1.2956 mL
	60 mM	0.0432 mL	0.2159 mL	0.4319 mL	1.0796 mL
	80 mM	0.0324 mL	0.1619 mL	0.3239 mL	0.8097 mL
	100 mM	0.0259 mL	0.1296 mL	0.2591 mL	0.6478 mL

Keywords

Mavorixafor hydrochloride

8 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mavorixafor hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

FDA-Approved Anticancer Drug Library

Chemokine Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Mavorixafor hydrochloride

All CXCR Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mavorixafor hydrochloride Related Classifications

HY-50101C Related Classifications